Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated ...

Halozyme’s recurring revenue, product strength, and market resilience point to solid upside even with debt and tariff risks.

Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year. IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $ ...

OmniAb, Inc. today announced that management will be participating in five investor conferences over the coming weeks. H.C. Wainwright 1st Annual Royalty Company Virtual Conference, May 13. Management ...

Scorpius Holdings, Inc (OTC: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided ...

Ionis Pharmaceuticals IONS reported first-quarter 2025 adjusted loss of 75 cents per share, narrower than the Zacks Consensus ...

It offers a unique approach to addressing this challenging and often distressing symptom. Agitation frequently occurs in ...

If you are looking for the perfect gift for mom this year, check out the following products she will surely enjoy.

About Ligand Pharmaceuticals. Ligand is a biopharmaceutical company enabling scientific advancement through supporting the ...

Q1 2025 Earnings Conference Call May 1, 2025 11:00 AM ETCompany ParticipantsScott Parsons - Senior Vice President, ...

Blueprint Medicines Corporation today reported financial results, provided a business update for the first quarter ended March 31, 2025, and provided corporate ...